SEC Form 4 · accession 0001209191-15-080283
ReShape Lifesciences Inc. · RSLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dan W Gladney
Officer — Chief Executive Officer · Director
Period of report
Nov 12, 2015
Accepted (ET)
Nov 16, 2015 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 12, 2015 | P | 750,000 | $0.18 | A | 750,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.25 | holding | — | — | — | Oct 28, 2016 | Oct 28, 2025 | Common Stock | 7,750,000 | 7,750,000 | D |
Explanation of responses
- F1The price reported is the weighted average purchase price for the transaction reported. The purchase prices ranged from $0.175 to $0.181. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range.
- F2Vests as to 25% one year from the date of the employment agreement on the date noted and thereafter in cumulative installments of 1/36th per month.